Institutional investors purchased a net $1.8 million shares of MACK during the quarter ended September 2014. This may signal that the smart money is gaining interest in this company as the 52.32% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CONSONANCE CAPITAL MANAGEMENT LP Bought 1.5 Million shares of Merrimack Pharmaceuticals...